Eli Lilly’s $3.8 Billion Vaccine Bets: Here’s the Big Story Many Investors Are Missing
Two drugs account for almost two thirds of Eli Lilly‘s (NYSE: LLY) top line, generating about $12.8 billion in revenue in the first quarter of 2026. The two drugs, Mounjaro and Zepbound, are also growing strongly, with sales increasing 125% and 80% year over year, respectively, in the first quarter. So why should investors care…